pharmacie et médicaments – Avis de la HAS sur les traitements innovants contre le myélome multiple

This written question concerns the High Authority for Health's (HAS) evaluation of innovative medical treatments for multiple myeloma, a type of blood cancer. The procedure seeks to clarify the status and accessibility of new therapies to ensure patients receive the most effective care. This primarily affects patients with multiple myeloma, healthcare providers, and pharmaceutical companies involved in developing oncology treatments in France.